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classiﬁcation
Introduction
The major goal of the Summit was to foster discussion among
the participants in an effort to reach consensus on important
topics in the prevention, diagnosis, and treatment of osteoar-
thritis (OA) and to highlight future directions for research. To
that end, long breakout sessions were held at the end of both
days of the summit. Here, we provide a summary of the
sessions. To focus the discussion, participants were challenged
to develop answers to questions posed by the co-chairs
(addressed below). Much of the discussion was also focused
around a proposal from John Hardin of the Arthritis
Foundation to develop a concentrated, multidisciplinary,
multi-institutional effort centered on the stabilization of
cartilage matrix after joint trauma. Applying candidate
pharmacologic agents and detecting the resulting stabilization
with new imaging andmolecular biomarkers could be a way to
achieve concrete progress in preventing OA (see John
Hardin’s article elsewhere in this supplement).
Classiﬁcation and Pathophysiology
Question 1: What criteria should be used to develop a
classiﬁcation system for OA?
A classiﬁcation system is essential for all aspects of OA
and needs to be applicable for detection and diagnosis, as
well as for assessing the potential utility of an intervention.
The current classiﬁcation system for OA dichotomizes on
primary (“natural”) and secondary, but secondary is
problematic because it could be argued that all OA is
secondary to something, e.g., genetic factors and age.
Perhaps a better way of dichotomizing OA is to employ
the terms used for animal models of the disease: spontane-
ous or induced OA. The latter would include a speciﬁc
event or identiﬁable intervening process, for example, a
joint injury that led the patient to seek clinical evaluation.
Classiﬁcation might also seek to combine symptoms
(e.g., stiffness, pain, and functional limitations) with
associated structural abnormalities in the same joint (as
documented by physical examination or imaging). Struc-
tural or joint tissue compositional abnormalities also could
be identiﬁed indirectly, prior to the stage at which structural
changes can be detected by physical exam or imaging,
perhaps through genotyping or the use of biomarkers
detected in urine or blood samples.
The common imaging modalities and associated ﬁnd-
ings employed for diagnosis and classiﬁcation of OA are
well documented, including radiographic ﬁndings of joint
space narrowing, osteophytes, and joint malalignment.
Symptoms have been classiﬁed based on the presence and
type of pain: aching, discomfort, stiffness, unease, trouble-
some, and “awareness” of the joint or on the severity of the
symptoms—intermittent versus constant pain, fatigue, de-
pression and anxiety, loss of sleep, and stiffness.
A classiﬁcation system for OA could be reﬁned by
including the stage of the disease (e.g., preclinical molec-
ular/metabolic, pre-radiographic, radiographic, and joint
replacement stages). One could imagine a classiﬁcation tree
with a hierarchical approach. The recently proposed
classiﬁcation based on genetics, estrogen and menopausal
status, and aging may be too general and nonspeciﬁc to be
of use as a classiﬁcation system. Similarly, classiﬁcation
systems based on the pathophysiological mechanism (e.g.,
biomechanical, injury, inﬂammation, and aging) or based on
speciﬁc joint tissue involvement are premature at this time.
From the standpoint of clinical trials, all patients should
be included regardless of classiﬁcation. However, it was
suggested that phenotypic classiﬁcation of patients should
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be considered when selecting participants for clinical trials.
For example, an intervention that is designed to target
synovitis should be studied in patients with evidence of
active synovial inﬂammation, since it is not always present
throughout the clinical course of OA. Likewise, a therapy
that is designed to target bone remodeling or cartilage repair
optimally should be studied in patients with evidence of
active involvement of these tissues.
Question 2: Should function and symptoms be included in
the classiﬁcation system?
We can gain insights from the utility of incorporation of
functional and symptomatic criteria into classiﬁcation
systems for patients with rheumatoid arthritis (RA). For
patients with OA, functional assessments have been
developed for clinical subsets of patients with speciﬁc sites
of joint involvement. Functional assessments are usually
self-reported, and self-reporting enables thorough and timely
follow-up, but behavior modiﬁcation should be assessed
functionally by a trained observer when used as part of clinical
trials. Differences between self-reports of function and
objective measures of function have been reported and should
be considered. Psychosocial patient characteristics affect self-
reported functional outcomes more than they affect objective
measures. Studies should include both standard self-reported
measures, such as, WOMAC function, but also joint speciﬁc
measures of function, such as the 6-min walk distance for knee
OA.
Question 3: How do patient expectations and public health
needs inﬂuence treatment selection and efﬁcacy?
Meeting patient expectations with respect to the use of
speciﬁc therapies must be balanced with evidence validated
by an appropriate experimental assessment and testing (e.g.,
no arthroscopy for a degenerative meniscus without
mechanical symptoms). Patient expectations center on a
number of issues. For example, relief from pain and
functional limitations are paramount, but concern about
the future and the desire for the “least possible intervention”
without making symptoms worse are important consider-
ations as well.
Patients must be educated and informed regarding the
structural and symptomatic changes that accompany the
onset and progression of OA so that they have realistic
expectations with respect to how these changes will affect
their quality of life. With this information, they may more
readily and realistically accept the known beneﬁts of
pharmacologic and nonpharmacologic interventions, such
as exercise and weight loss, in preventing the disease.
Patient expectations should also be considered in the
regulatory approach to demonstrate safety and efﬁcacy of
new OA treatments. Patients may well be less risk averse
than investigators, institutional review boards, and the FDA
when considering the value of new preventative, diagnostic,
or treatment modalities for OA and the need to participate in
clinical trials that would personally affect their disease.
From a public health standpoint, the need exists to
emphasize the beneﬁts of nonpharmacological therapies
such as decreased obesity and increased activity and to
develop a better understanding of the time course of
initiation and progression of the disease. The impact of
the doctor–patient relationship in OA should also be
studied. Physicians typically do not have time to provide
adequate lifestyle advice to the patient, nor does the
physician have the tools to monitor adequately the impact
of lifestyle changes on patient expectations and outcomes.
Treatment approaches that integrate multidisciplinary health
professionals rather than second and third opinions from
other physicians would beneﬁt patients with OA, especially
in the absence of any current effect management algorithm
for chronic OA.
Development of such sustainable, effective strategies
should rely on a combination of biomechanical intervention,
pharmacological agents, and weight loss with exercise
programs with the goal of prevention or substantial delay in
the need for joint replacement. Public health research should
focus on the duration, safety, cost, and feasibility of such
combined prevention and treatment approaches and consider
behavioral economics, e.g., short-term incentives to lose
weight as a means of accomplishing long-term sustainability.
Other public health issues surrounding OA include:
reimbursement, reactive versus proactive therapy, presence
of comorbid diseases, the need for an effective chronic
disease management model, issues arising from OA patients
repetitively cycling through the health care system without
appropriate management of their disease, and the impact of
new shifts in OA prevalence with prevalence rising
dramatically in younger populations.
Assessment
Questions 4 and 5: What is the current status of tools to
assess joint composition, structure, and function and how
can they be used in diagnosis? and What are the optimal
tools for diagnosis and for monitoring progression and
response to therapy?
Imaging should be used to provide structural outcome(s)
and in some studies may be used as a primary outcome
along with pain and function. Recent advances in imaging
techniques have been applied to the study and evaluation of
patients with OA, and many of the most informative
outcomes from imaging are just now coming to fruition in
terms of use in clinical trials and consideration by the FDA
for drug approval. Magnetic resonance imaging (MRI)
allows evaluation of “cartilage health” using techniques
that include delayed gadolinium-enhanced MRI of cartilage,
so-called dGEMRIC, T2 mapping, and T1rho. These are
widely available metrics and so are applicable for multi-site
studies, though with dGEMRIC the risk imposed by double
dose contrast and its use in patients with renal impairment
at risk for the development of nephrogenic systemic
sclerosis must be considered. Additional imaging modalities
include optical coherence tomography, confocal microsco-
py, and Ramon spectroscopy, all of which are advancing to
expand the global view of the joint in health and disease.
MRI techniques and ultrasound have also been used to
assess synovial pathology, and evidence exists that the
presence of synovial inﬂammation is associated with less
favorable clinical outcomes. Chemical exchange saturation
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transfer also shows promise as a valuable imaging tool, but
is much less widely available.
Techniques for quantifying and assessing the structural
and material properties of peri-articular bone have also been
developed. Regional BMD is amenable to measurement,
and additional techniques using X-ray, CT, and MRI are
widely available. Mechanical assessments of tissues could
include ﬂuoroscopic imaging and dynamic MRI.
Except for PET imaging (which is limited by the expense),
noninvasive tools for identifying and monitoring cell death
have insufﬁcient resolution to quantify cell death. Imaging cell
death using Annexin V is a possibility, as are the use of DNA
fragments and other available biomarkers (e.g., vimentin) [3].
Measurement of streaming potential in cartilage offers a
precise and reproducible method of measuring proteoglycan
content. However, the main limitation of this approach is the
potential need for repeat arthroscopies.
Techniques for sensory assessment in patients with OA also
are available and have been particularly informative in assessing
the mechanisms of nociception in animal models of OA.
Considerable research in recent years has focused on the
development of biomarkers that can be applied to gain
insights into pathogenic mechanisms underlying OA;
importantly, biomarkers can be utilized to assess the effects
of therapeutic interventions. Biomarkers can be deﬁned in
general terms as objective indicators of normal biologic
processes, pathogenic processes, or pharmacologic
responses to therapeutic interventions and have the potential
to decrease the length and cost of trials. Characteristically,
biomarkers have been identiﬁed as molecules or molecular
fragments that are released as a result of joint tissue
metabolism, but additional markers are in development that
are related to additional intra-articular processes such as
inﬂammation. Discussions included review of the Osteoar-
thritis Biomarkers Network, which is a consortium of ﬁve
sites, funded by the National Institutes of Health/National
Institute of Arthritis, Musculoskeletal, and Skin Disease
(NIH/NIAMS). Its goal is to develop and characterize new
biomarkers and to reﬁne existing OA biomarkers for
clinical trials to gain insights into OA pathogenesis (A
more detailed discussion and application of biomarkers is
provided in the article by Linda Sandell in this supplement).
Treatment
Question 6: What speciﬁc pathophysiological processes
responsible for tissue alterations and symptoms should be
therapeutically targeted?
Processes that should be considered include synovitis,
cartilage loss, bone remodeling (bone marrow lesions, peri-
articular bony changes), osteochondral repair response, muscle
weakness, and abnormalities in the meniscus, ligaments and
entheses with or without associated joint laxity. The ideal
therapeutic needs to target pain and related symptoms in
addition to joint structure and to be effective within a reasonable
time. Importantly, OA is a “whole joint” disease that affects all
of the tissue components of the joint. In individual patient
subsets, a single tissue, e.g., cartilage or bone, may be the
primary target of the pathologic process, but optimal therapies
may need to target multiple tissues.
Question 7: What are the optimal therapeutic targets?
Organizing OA phenotypes into “syndromes” provides a
potentially useful approach in constructing a rational
framework for optimizing treatments. The so-called meta-
bolic syndrome that affects cartilage homeostasis, bone
remodeling, and inﬂammation would be such an example.
Other potential organizing principles include mechanical
and structural syndromes (e.g., malalignment, obesity, joint
incongruity, and joint instability); age-related (including
sarcopenia); and inﬂammatory (associated with synovitis).
Question 8: What interventions (medical and surgical) can be
employed to prevent or slow the progression of OA and when
should they be employed?
Given that many animal models of OA are joint injury
models, human OA “syndromes” that are initiated by acute
joint injury represent useful conditions for understanding
the pathophysiological processes associated with OA and
for evaluating the effect of therapeutic interventions. For
example, certain acute joint injuries in humans are
accompanied by an increase in aggrecan (fragment) release
from articular cartilage. This process is dependent on the
activity of “aggrecanses” that can be potentially targeted
with inhibitors and the efﬁcacy of the intervention assessed
using presently available imaging techniques and/or blood
and urine biomarkers. Collagen degradation that may lead
to irreversible cartilage damage can also be observed shortly
after acute joint injury, and therapies that target this
pathologic process can be assessed. "Is there target
engagement?" is a critical question that may well depend
on the ability of an imaging outcome to show preserved
health of the cartilage.
Prevention is generally ignored in the consideration of
therapeutic intervention strategies. The comparative cost-
effectiveness of different strategies is important; effective
interventions exist for many pain-related problems, such as,
pain catastrophizing, but these are rarely used. Weight loss for
obese knee OA patients is effective for pain (see the article by
Stephen Messier in this supplement). Reimbursement is a
major obstacle in implementing prevention measures. Will
insurance companies pay for supervised exercise and weight
loss intervention? Such an approach is not currently consid-
ered a “medical beneﬁt,” and so would be considered a special
case by third party payers. NIH-funded randomized clinical
trials of other nonpharmacological interventions are ongoing,
so hopefully the necessary additional data will be forthcoming.
Many pharmacological agents that target synovial inﬂam-
mation and cartilage and bone remodeling are available. In
general, they are designed for systemic administration. In
cancer therapy, liposomes and nanoparticle delivery systems
are being used for targeting speciﬁc sites. Similar approaches
for local intra-articular delivery of agents to affected joints are
being developed for treatment of OA.
Surgical interventions are improving steadily, including the
advent of distraction technology to temporarily unload the joint
and allow a period of prolonged healing. The role of excessive
joint loading in the onset and progression of OA has been
extensively studied. Importantly, both osteotomies and joint
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distraction have been shown to modify joint mechanics and
loading and tomodify the course and rate of progression of OA.
Surgical techniques to correct femoral acetabular impingement
hold promise for improving the outcomes in patients with hip
joint structural abnormalities, but it is unclear at this time which
forms of malalignment are risk factors for OA and whether the
surgical procedures will avert the development of OA.
Outcome Measures and Clinical Assessments
Question 9: What measures should be used as endpoints in
clinical trials of patients with OA?
Demonstrating the efﬁcacy of early intervention is
critical to insure a major breakthrough in OA. However,
given the state of the current art, it is more likely that
patients would be enrolled who already have clinical and/or
structural evidence of OA and for whom the intervention is
designed to slow or prevent the OA progression. Effective
endpoints would be pain and function that can be measured
using a variety of assessment tools including Western
Ontario and McMaster Universities Osteoarthritis Index:
WOMAC; pain characterization (McGill short form);
Intermittent and Constant Osteoarthritis Pain (ICOAP)
questionnaire that measures pain comprehensively in the
knee and hip; and Knee and Hip Injury and Osteoarthritis
Outcome Scores. Good performance based measures in-
clude Timed Up and Go, timed walk (e.g., 6 min), stair
climb and chair stands. Optimal measures of physical
performance need to incorporate assessment of functional
activities that are relevant to the patient’s needs. An
effective therapy would improve performance beyond just
joint function.
To power a trial, it would be best to pick two primary
endpoints, one symptom based and one structure based. To
gain maximum information, the suggestion would be to use all
the technology (and measures) that can possibly be incorpo-
rated; however, requiring too many patient-reported outcomes
becomes a burden to study participants who are often elderly.
In a drug development program, the number of outcomes is
highly focused rather than broad as for an exploratory study.
Question 10: Are different endpoints needed for speciﬁc
clinical subsets?
Both ﬂoor and ceiling effects may apply for different
patient subsets. In quality of life utilities, for example, the SF-
60 has a ﬂoor effect so it is not as discriminant in disease
populations, while the EQ-5D has a ceiling effect so it is not as
discriminant in healthy people. The NIH PROMISE study can
help avoid ceiling/ﬂoor effects. An OA computer-adapted tool
has been developed to avoid ﬂoor and ceiling effects [5]. The
self-reported The Compendium of Physical Activity [1] has
been translated into joint loads. Accelerometry can provide
objective physical activity data and shows that self-reports
exaggerate levels of activity [4]. Joint shape and how it
impacts underlying tissue architecture is another emerging
outcome [2].
Question 11: Who should deﬁne the priorities?
Although the obvious answer is the patients, the entities
that pay the medical bills realistically deﬁne the priorities.
However, based on current limitations in the FDA regulatory
approach to OA treatments, candidate therapies cannot be
effectively prioritized. Working on the basic biology of the
disease will help advance this effort, as will the OARSI FDA
OA initiative.
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